| Gene |
[PARK2](/genes/park2) |
| UniProt |
O60260 |
| PDB |
4K7D, 5CAW, 6GSh |
| Mol. Weight |
52 kDa (465 amino acids) |
| Localization |
Cytosol, mitochondrial outer membrane (upon activation) |
| Family |
RBR family (Ring-Between-Ring) E3 ubiquitin ligases |
| Diseases |
[Parkinson's Disease](/diseases/parkinsons-disease), [Autosomal Recessive Juvenile Parkinsonism (ARJP)](/diseases/autosomal-recessive-juvenile-parkinsonism) |
PARK2, also known as parkin, is a cytosolic E3 ubiquitin ligase that plays a critical role in mitochondrial quality control through the regulation of mitophagy—the selective autophagy of damaged mitochondria. Encoded by the PARK2 gene, parkin is one of the most frequently mutated proteins in early-onset familial Parkinson's disease (PD), with loss-of-function mutations causing autosomal recessive juvenile parkinsonism (ARJP) characterized by onset before age 40 .
The parkin protein is a member of the RBR (Ring-Between-Ring) family of E3 ubiquitin ligases, characterized by a unique catalytic mechanism involving the transfer of ubiquitin directly from an E2 enzyme to substrates through a thioester intermediate. Parkin's function is intimately linked to PINK1 (PTEN-induced kinase 1), as PINK1 recruits and activates parkin to damaged mitochondria, forming the core of the PINK1-PARKIN mitophagy pathway that is essential for neuronal survival .
Parkin possesses a distinctive multi-domain architecture that enables its regulatory functions:
¶ Domain Organization
-
N-terminal Ubiquitin-like (Ubl) domain (residues 1-76)
- Structural similarity to ubiquitin
- Regulates parkin activity through autoinhibition
- Phosphorylated by PINK1 at Ser65
-
RING0 domain (residues 141-218)
- Unique to parkin family
- Contains the "repressor element" that maintains autoinhibition
- Essential for interaction with phosphorylated ubiquitin
-
RING1 domain (residues 237-284)
- Coordinates E2-ubiquitin binding
- Contains active site cysteine (Cys254)
-
In-Between-Ring (IBR) domain (residues 327-379)
- Intermediate domain with zinc-finger motif
- Facilitates substrate recognition
-
RING2 domain (residues 415-465)
- Contains catalytic cysteine (Cys431)
- Forms thioester intermediate with ubiquitin
- Autoinhibited conformation: The Ubl domain binds to the RING0 domain, blocking substrate access
- Open conformation: PINK1 phosphorylation releases autoinhibition
- Phospho-ubiquitin binding: Phosphorylated ubiquitin binds to the RING0 domain, further activating parkin
- Zinc coordination: Multiple zinc-finger motifs stabilize the structure
- Phosphorylation: Ser65 (by PINK1) activates parkin activity
- Ubiquitination: Auto-ubiquitination for proteasomal degradation
- S-nitrosylation: Nitric oxide-mediated regulation
- Oxidative modifications: Cysteine oxidation affects activity
Parkin's primary function is in mitophagy—the selective degradation of damaged mitochondria:
- Mitochondrial damage detection: In healthy mitochondria, PINK1 is imported and degraded
- PINK1 stabilization: Upon damage, PINK1 accumulates on the outer mitochondrial membrane
- Phosphorylation: PINK1 phosphorylates ubiquitin (Ser65) and parkin (Ser65)
- Parkin recruitment: Phospho-ubiquitin binds parkin, recruiting it to mitochondria
- Activation: Phosphorylated parkin undergoes conformational change
- Ubiquitination: Parkin ubiquitinates mitochondrial outer membrane proteins
- Autophagic recognition: Ubiquitinated mitochondria are recognized by autophagy receptors (p62, OPTN, NDP52)
- Lysosomal degradation: Autophagosome-lysosome fusion eliminates damaged mitochondria
Parkin ubiquitates numerous mitochondrial substrates:
- Mitochondrial fusion proteins: MFN1, MFN2, OPA1
- Import machinery: TOM20, TOM22, TIMM44
- Anti-apoptotic proteins: MCL1, BCL2
- Metabolic enzymes: ZFP106, STUB1
Beyond mitophagy, parkin participates in general protein quality control:
- Proteasomal degradation: Tags misfolded proteins for degradation
- Aggresome targeting: Directs protein aggregates to aggresomes
- ERAD pathway: Participates in endoplasmic reticulum-associated degradation
- Lysosomal targeting: Facilitates trafficking to lysosomes
- Mitochondrial dynamics: Regulates mitochondrial fission and fusion
- Energy metabolism: Maintains ATP production through quality control
- Calcium homeostasis: Regulates mitochondrial calcium handling
- Apoptosis regulation: Prevents intrinsic apoptosis pathway
Parkin mutations are the most common cause of early-onset PD:
- Inheritance: Autosomal recessive (biallelic mutations required)
- Prevalence: ~50% of early-onset PD (<20 years) cases
- Mutation types: Deletions, point mutations, copy number variations
- Hotspot regions: Exons 2-4 (Ubl domain), Exons 6-8 (RING domains)
- Age of onset: Typically 20-40 years
- Initial symptoms: Tremor, dystonia, bradykinesia
- Disease progression: Slower than idiopathic PD
- Levodopa response: Excellent initial response
- Motor fluctuations: Early development of wearing-off
- Non-motor symptoms: Sleep disorders, psychiatric features
- Neuronal loss: Severe loss of dopaminergic neurons in substantia nigra pars compacta
- Lewy bodies: Often absent or atypical
- Mitochondrial abnormalities: Prominent in patient tissue
- Muscle biopsy: Often shows mitochondrial dysfunction
The PINK1-PARKIN pathway is central to mitochondrial dysfunction in PD:
- Reduced clearance of damaged mitochondria
- Accumulation of dysfunctional mitochondria
- Increased oxidative stress
- Energy deficit
- Reduced ATP production
- Impaired complex I activity
- Altered mitochondrial membrane potential
- Increased ROS production
Parkin dysfunction is implicated in:
- Impaired mitophagy contributes to amyloid pathology
- Mitochondrial dysfunction in AD models
- Genetic interactions with APP processing
- Mitochondrial quality control defects
- Reduced mitophagy in motor neurons
- Interactions with SOD1 pathology
- Mutant huntingtin disrupts parkin function
- Impaired mitochondrial dynamics
- Therapeutic target potential
| Partner Protein |
Interaction Type |
Functional Consequence |
| PINK1 |
Kinase-substrate |
Phosphorylation activates parkin |
| Phospho-ubiquitin |
Binding |
Recruitment to mitochondria |
| E2 enzymes (UbcH7, UbcH8) |
Catalytic |
Ubiquitin transfer |
| p62/SQSTM1 |
Autophagy receptor |
Links ubiquitinated substrates to autophagosome |
| OPTN |
Autophagy receptor |
Autophagic clearance |
| NDP52 |
Autophagy receptor |
Selective mitophagy |
| MFN1/2 |
Substrate |
Ubiquitination, degradation |
| BCL2 |
Anti-apoptotic |
Regulates apoptosis |
| CDC37 |
Chaperone |
Complex assembly |
| HSP70 |
Chaperone |
Protein quality control |
- Mitochondrial damage → mitochondrial membrane depolarization
- PINK1 stabilization → accumulation on outer mitochondrial membrane
- Phospho-ubiquitin generation → PINK1 phosphorylates mitochondrial ubiquitin
- Parkin recruitment → phospho-ubiquitin binds parkin's RING0
- Parkin activation → Ser65 phosphorylation induces conformational change
- Substrate ubiquitination → mitochondrial proteins tagged with ubiquitin
- Autophagy receptor recruitment → p62, OPTN, NDP52 bind ubiquitin chains
- Autophagosome formation → LC3 lipidation, membrane recruitment
- Lysosomal fusion → mitochondrial degradation
- NF-κB signaling: Parkin regulates inflammatory responses
- WNT signaling: Interacts with β-catenin degradation pathway
- DNA repair: Involved in genome stability maintenance
- TRAF6 signaling: Regulates innate immune responses
- AAV-PARK2 delivery: Adeno-associated virus-mediated gene transfer
- CRISPR-CAS9: Correcting pathogenic mutations
- Promoter optimization: Neuron-specific expression
- PINK1 activators: Enhance parkin recruitment
- Ubiquitin analogs: Bypass PINK1 requirement
- Allosteric modulators: Activate parkin directly
- NAD+ precursors: Enhance mitochondrial function
- mTOR inhibitors: Induce autophagy
- UTI derivatives: Promote mitophagy
- Statins: May enhance parkin function
- Lithium: Promotes autophagy
- Rapamycin: mTOR inhibition enhances mitophagy
- PARK2-/- mice: Show mild phenotypes, sensitivity to mitochondrial toxins
- PINK1-/- mice: Severe deficits in mitophagy
- Double knockout: Synergistic effects
- Parkin overexpression: Protective in toxin models
- Mutant parkin: Recapitulate ARJP phenotypes
- Humanized models: Expressing patient mutations
- Age-related motor decline
- Mitochondrial dysfunction
- Reduced striatal dopamine
- Behavioral abnormalities
- Plasma parkin levels: Reduced in PD patients
- CSF markers: Impaired mitophagy markers
- Muscle biopsy: Mitochondrial respiratory chain defects
- Fibroblast studies: Patient-derived cells show mitophagy defects
- iPSC models: Dopaminergic neurons recapitulate disease features
- Blood biomarkers: Oxidative stress markers
- Kitada et al., PARK2 mutations in familial Parkinson's disease (1998)
- Shimura et al., Ubiquitin ligase activity of PARK2 (2000)
- Narendra et al., PARKIN and mitophagy (2010)
- Matsuda et al., PINK1-PARKIN pathway in mitochondrial quality control (2010)
- Youle and Narendra, Mechanisms of mitophagy (2011)
- Pickrell and Youle, PARKIN and PINK1 in Parkinson's disease (2015)
- Vincow et al., The PINK1-PARKIN pathway in vivo (2013)
- Geisler et al., PINK1 and PARK2 in mitophagy (2010)
- Scarffe et al., PARK2 and mitophagy (2014)
- McCoy and Cookson, Mitochondrial dynamics and PARKIN (2012)
Parkin plays crucial roles in synaptic function:
- Regulates presynaptic vesicle release
- Controls postsynaptic receptor trafficking
- Modulates dendritic spine morphology
- Essential for long-term potentiation (LTP)
- Maintains mitochondrial distribution along axons
- Regulates transport vesicle dynamics
- Controls synaptic vesicle replenishment
- Protects against axonal degeneration
Dopaminergic neurons are particularly dependent on parkin:
- High metabolic demands require efficient mitophagy
- Spontaneous pacemaking increases mitochondrial stress
- Elevated ROS production requires quality control
- Axonal arborization demands extensive mitochondrial network
¶ Fusion and Fission Regulation
Parkin modulates mitochondrial morphology:
- MFN1/2 ubiquitination: Tags for degradation, shifts balance toward fission
- OPA1 processing: Affects inner membrane fusion
- DRP1 recruitment: Promotes fission events
- Dynamics balance: Critical for neuronal survival
- Coordinates with PGC-1α pathway
- Maintains mitochondrial DNA replication
- Regulates protein import
- Controls lipid composition
¶ Clinical and Therapeutic Considerations
- Sequencing: Comprehensive PARK2 mutation analysis
- Copy number variation: Detects deletions/duplications
- Interpretation: Distinguishes pathogenic from benign variants
- Peripheral blood mononuclear cells: PARKIN expression studies
- Muscle mitochondria: Respiratory chain analysis
- Fibroblast cultures: Mitophagy assays
- Levodopa therapy: Symptomatic relief
- MAO-B inhibitors: Dopamine metabolism modulation
- Dopamine agonists: Receptor stimulation
- Physical therapy: Motor rehabilitation
- Gene therapy: AAV-PARK2 delivery in clinical trials
- Protein aggregation inhibitors: Enhance clearance
- Mitochondrial protectants: Antioxidants
- Cell replacement: Stem cell therapies
- Blood-brain barrier: Drug delivery limitations
- Dosage optimization: Balancing efficacy and toxicity
- Mutation-specific effects: Variable response to treatments
- Long-term outcomes: Disease progression despite treatment
- Ubiquitination assays: In vitro ligase activity
- Phosphorylation analysis: PINK1 kinase assays
- Interaction mapping: Co-immunoprecipitation
- Structural studies: X-ray crystallography, cryo-EM
- HEK293 cells: Heterologous expression
- SH-SY5Y neurons: Differentiated neuronal models
- Primary neurons: Mouse/rat cortical cultures
- Patient fibroblasts: Disease-relevant context
- C. elegans: Genetic tractability, short lifespan
- Drosophila: Conservation of pathway
- Zebrafish: Developmental studies
- Mammalian models: Comprehensive phenotyping
- Why are dopaminergic neurons selectively vulnerable?
- Mechanism of parkin activation in physiological conditions
- Therapeutic window for parkin activation
- Biomarkers for treatment response
- Protein engineering: Hyperactive parkin variants
- Targeted degradation: PROTAC molecules
- Gene editing: CRISPR base editors
- iPSC therapy: Patient-derived neurons
¶ Neuroinflammation and Parkin
Parkin regulates neuroinflammation:
- TLR signaling: Modulates innate immune responses
- Cytokine production: Controls inflammatory mediators
- Microglial activation: Affects glial cell function
- NLRP3 inflammasome: Regulates inflammasome activity
Common inflammatory pathways:
- NF-κB signaling: Central to neuroinflammation
- MAPK pathways: Stress-activated cascades
- Complement system: Immune surveillance
¶ Oxidative Stress and Mitochondrial Function
Parkin protects against oxidative stress:
- NADPH oxidase: Modulates ROS production
- Antioxidant responses: Nrf2 pathway interactions
- DNA repair: Maintains genome integrity
- Protein oxidation: Prevents accumulation of damaged proteins
Specific effects on mitochondria:
- Complex I: Primary site of ROS generation
- mtDNA: Vulnerable to oxidative damage
- Membrane lipids: Peroxidation cascade
- Calcium handling: ROS-Ca2+ feedback
Parkin (PARK2) is a pivotal E3 ubiquitin ligase essential for mitochondrial quality control through the PINK1-PARKIN mitophagy pathway. Loss-of-function mutations cause autosomal recessive juvenile parkinsonism, highlighting its critical role in dopaminergic neuron survival. The protein's unique RBR domain architecture enables regulated ubiquitin ligase activity, with PINK1-mediated phosphorylation serving as the key activation trigger. Beyond mitophagy, parkin participates in diverse cellular processes including protein quality control, apoptosis regulation, and synaptic function. Understanding parkin biology offers therapeutic opportunities for Parkinson's disease and other neurodegenerative conditions characterized by mitochondrial dysfunction.